Solving the 'What Next' Problem in Health Diagnostics: Interview with Vero Bioscience CEO Paul Coletta

Vero Bioscience’s "Vero Compass" platform bridges the gap between diagnostic health insights and actionable interventions by measuring the biological age of individual organs through a single blood draw. By analyzing protein signatures, the technology identifies organ-specific vulnerabilities, allowing for evidence-informed interventions that are tracked for efficacy over time. This approach shifts the healthcare paradigm from reactive disease management to proactive, data-driven health optimization. Beyond technical innovation, the discussion highlights critical startup strategies, including the necessity of building long-term investor relationships, hiring mission-driven "patriots" rather than mercenaries, and maintaining a "think big, start small" operational philosophy. Effective leadership requires influencing change, while board governance should focus on strategic value-add rather than day-to-day management, ensuring the company remains agile and focused on its core mission of ending age-related chronic disease.